**[미래에셋 제약/바이오 김승민]**
**10/6 Daily**

[https://t.me/bioksm](https://t.me/bioksm)


 **글로벌 바이오/제약**
────────────────────
 [Gate Bioscience, Lilly와 신약개발 계약을 $870mn 이상으로 확대](https://news.google.com/rss/articles/CBMiygFBVV95cUxQMS10YTFmSVN4T3hpaW9qQUYwNzZha20yWTlzMlg0MFRHUklNd0V2dnRzRzV1LTlnbVNINDZoR2wtaWlOYzJuUDhLNDVFQmI3R1JOSFg2ZmVXM1oxd3RsOHIybzJnUkRDLUlKM2YweGNYeThzZ2txV3M3QVhxeFZRakl6SHhOVjA5SV9SSVdscWNyeTctTXdGNmdYdTdSUjQ0czhTYjlWSDAwQlB3QUJKMHdXWEVVTUhRNmJocWphemZuSlliYTJlUGp3?oc=5)

 [Alector, 로슈의 파킨슨병 치료제 라이선스 최대 $1.27bn 규모에 주가 급등](https://news.google.com/rss/articles/CBMitgFBVV95cUxQOFIzVzd3emp4eHRpVUEtR0NSUlJnQ19ldnVlU0M5U3daYk1WRmktRy1UMTNnUWR4OFNqcktyMUR1cjR3dTJTX0trUFZhZTVjOUN3WERVMU5fcHRkaENiTk1oS3hPdFJWU21VMVQ2LU81VUVYaTVBMURIRUpXbHRyT1A1ZzFFQndNY2dmb2NQYkQtYjFIdmpQM0FxcXdKUXg5bHV5bnhzeHJjby1JNFlGdUlScnRHQQ?oc=5)

[▶️ Shionogi, 희귀 질환 상용화 바이오텤 기업 Intrabio를 $2bn에 인수](https://endpoints.news/shionogi-to-pay-2b-for-intrabio-a-commercial-rare-disease-biotech/)

 [GE Healthcare, Sofie Biosciences  $925mn에 인수하며 방사성의약품 사업 강화](https://news.google.com/rss/articles/CBMi0AFBVV95cUxOOVBLWFpqcFRYNkNxV3A3cVU1aUhFdFNwX2VMbXVXZV9XanZxc20ycWpYS2Qyc004UDFHRGJkQlpsZExWV055TUpmREpXMGl0LVh4aS1Lci1HTTZjSG5SbDQzSVhBdXhKTzZ2MU4xejByTHpWZkx6ZGZycVd4V0I2SzlqQlZKWVJMSzVHVVJSdlVJZ1VhQUxsYVJLVGFfeUlxU2VTOEpESUNRTEZtTGtYSDJ5cnRQdVB3aHFWWUE4QmRHTXpvWnRlNHJiZUpJQ2Q0?oc=5)

 [AbbVie·Genmab, 에프코리탐맙 병용요법이 신규 진단 미만성 대세포림프종 환자에서 R-CHOP 대비 무진행생존기간 유의하게 개선](https://www.prnewswire.com/news-releases/abbvie-and-genmab-announce-epcoritamab-in-combination-with-r-chop-demonstrates-significant-improvement-in-progression-free-survival-versus-r-chop-in-patients-with-newly-diagnosed-diffuse-large-b-cell-lymphoma-302898795.html)

 [Vaxcyte, 폐렴구균 백신 3상 성공으로 주가 급등](https://news.google.com/rss/articles/CBMi0gFBVV95cUxQXzdLQTZMb0ozQzgwUDRobE5wREZlV0ZiY0o5WG1uWk1qdWZ0d0RvbWh1UEZpdnBjT2RpR1pmSVo0dXpuY2dpdmQtMHpIZFViS0doUVZCZjY2NDNTSDd6bF9kTmxHSDVXRk93aG5RSS03LUc1NkMwenlXTDlJRlkyV2lJOUY0YlBPUTdhWjl2UVpiT0ZNVkhoNTdIbEJ6NXEwNENFUGlDdWxXYVFfdVp6Z2Z5eTBKODZBRF9DWThuT0gwMGlKanpYOWZydjBYQTZtSEE?oc=5)

 [CSL, 스위스 제약사 Alentis와 최대 $1.6bn 규모 희귀질환 치료제 거래 체결](https://news.google.com/rss/articles/CBMi5AFBVV95cUxPZG9HelZ5MGhEQ0N0OVhONHkzbFU0ZDlYN2FIcVdyR3BnUVVGWGRlVHZjRnlPNDhaci0yX05OTE8yTm9mZXlPcnplTGVhOGU5TlVmUm54UUFGYkQ3SFp4LU54TzBDTUtlbHpueFZKeUNRUnIyZHRYZG5Lcm9tejZmd25Fc0lITEFVbk9nNFo4WGJrUnNIUE1YS0VQc0ZBbjQ4NXdjb29GQ0VzWEJURmRyLW5JT2ZoQ2pHQlVZbWlJenhnYzFudmVnWjR0bV9FMGJobVEwelI1NTRyNVFYbVdmS2podFo?oc=5)

 [FDA, 공장 문제로 Novo의 혈우병 A 치료제 심사 연기](https://endpoints.news/fda-delays-novos-hemophilia-a-drug-review-over-factory-issues/)


 **한국 바이오/제약**
────────────────────
 [셀트리온, 3대 PBM 옵텀 손잡고 '옴리클로' 美 출시](https://www.hitnews.co.kr/news/articleView.html?idxno=79633)

 [삼성바이오 임금 협상 ‘평행선’ 노조 “3주간 2차 총파업” 예고](https://www.kihoilbo.co.kr/news/articleView.html?idxno=3036636)

 [바이오 재팬 내일 개막…삼성·셀트리온·롯데 '수주전'](https://www.yna.co.kr/view/AKR20261005035800017)

 ['M&A 큰손' 美 릴리, 미용시장까지 넘본다](https://news.google.com/rss/articles/CBMiWkFVX3lxTE5BQWxhcjVhcnRFRV9kXzRSb1pYaEdkVEJWNUZaaVExWDYxaGE5QW5Sam9UWUNGZXdoZGJER2JDRHQ2T1F0d0pxVVJ0OUcxeGNlUTZxaW9jOWthZw?oc=5)

 [HLB가 던지는 메시지 "특정 신약 좌절이 R&D 역량 상실 아니다"](https://www.hitnews.co.kr/news/articleView.html?idxno=79614)

 [삼성·SK·한미, 아태 제약·바이오 ‘빅딜’ 주역으로](https://news.google.com/rss/articles/CBMigwFBVV95cUxNS01DS2dPNmdlVUJtM0E1RGdGek9vb0lDdVJwMXM1N0l2SUQtYUdGc1pjTXhqdEc3VGJYejRlNnZuMnZLOGhJOVRMbENmTXN4Q0RFX2Frc2lOUVh0Q1ZiSEY4NXlKYndqVUhIWTNxM0c4OFF2azRoZEN0dTljRHlqV1pRWQ?oc=5)

 [윤태영 오스코텍 대표 “‘글로벌 스탠더드’에 맞는 바이오텍으로 성장하겠다”](https://www.thebionews.net/news/articleView.html?idxno=28735)